Partners

BSP Pharmaceuticals S.p. A. is focused on the development and manufacturing of anticancer drugs with high potency and cytotoxitc characteristics for the Pharmaceuticals Industry. BSP has been at the forefront in the fight against cancer since 2006. Innovation is the hallmark of BSP with investments in new technologies and production methods in a high-containment plant.

Website: www.bsppharmaceuticals.com

Hosting Partner

Mintz is a leading 600+ attorney law firm with deep experience in the life sciences industry. We help entrepreneurs launch and protect great ideas, facilitate funding opportunities, work with leading industry investors and underwriters in innovative financings and offerings, represent strategics, private equity firms, venture-backed businesses and entrepreneurs in buy- and sell-side M&A transactions, and counsel emerging as well as established and public companies in all aspects of their businesses, including intellectual property matters and regulatory approvals and compliance. For more on our firm and our work in Radiopharmaceuticals and ADCs, please visit our website

Website: www.mintz.com

Pipeline Innovation Partner

AVIPEP Therapeutics is a next-generation ADC company developing a pipeline
of AvDCs (Avibody Drug Conjugates) with a focus on improved tumor targeting
to deliver best-in-class clinical results and to better fight relapsed/refractory
disease. Privately-held and based in Cambridge MA and Melbourne VIC, AVIPEP
is eager to discuss co-development, asset out-licensing or investment. Our
proprietary Avibody™ platform will improve targeting and tolerability in all
manner of next-gen ADCs.

Website: www.avipep.com

Pipeline Innovation Partner

CytomX Therapeutics leverages its industry-leading PROBODY® conditional activation masking technology to pioneer a novel class of biologics and develop a multi-modality clinical pipeline including ADCs.

CX-2051, being studied in Phase 1, is a conditionally activated ADC directed toward EpCAM, a validated target with a narrow therapeutic index in conventional antibody approaches.

The Probody® platform is intended to unlock EpCAM as an ADC target and demonstrate the potential to significantly expand the ADC target landscape.

Website: www.cytomx.com

Pipeline Innovation Partner

Debiopharm is an innovation-focused, Swiss biopharmaceutical company that aims to develop innovative therapies to target high unmet medical needs in oncology and infection diseases. We establish partnerships with academic, biotech, and pharmaceutical institutions to bridge the gap between disruptive discovery products and international patient reach. Our ADC portfolio consists of carefully selected targets with 1st-in-class or best-in-class potential including a CD37-targeted ADC for AML/MDS (Debio 1562M) and a HER3-targeted ADC in solid tumors (Debio 0532).

Website: www.debiopharm.com

Pipeline Innovation Partner

Eigen aims to overcome the problem of tumor heterogeneity by modulating target expression to increase the efficacy and expand the therapeutic window of antigen-directed therapies (ADC, RLT). Eigen has built a platform to identify priming therapies, which upregulate antigen expression, and can be combined with antigen-directed therapies to improve patient responses, reduce ADC/RLT toxicity, and expand the responsive patient population. Eigen is actively developing priming agents for antigen targets in oncology.

Website: www.eigentx.com

Pipeline Innovation Partner

Escugen is a clinical-stage biotech company in Shanghai, China, focusing on the development of innovative ADCs, with its most advanced project (ESG401, an innovative Trop-2 ADC) in the PhIII clinical trials. EZWi-Fit®, Escugen’s proprietary linker-toxin family represents the State-of-the-Art ADC platform technology. With this technology, Escugen has established ADC pipelines against novel targets or validated targets with significant competition advantages. The platform technology has been licensed by multiple pharmaceuticals and biotech companies. Escugen is seeking opportunities for collaboration and partnership.

PIPELINE INNOVATION PARTNER

PINOTBIO develops novel treatments for patients resistant to existing therapies, focusing on antibody-drug conjugates (ADC). Utilizing robust R&D, we created the PINOT-ADC™ platform independently.

Our PINOT-payload, a unique Top1 inhibitor, offers dual mechanisms of action, while the PINOT-linker reduces normal tissue absorption and toxicity risks, common challenges in ADC development. Collaborating with partners, we leverage PINOT-ADC™ technology to advance new ADC-based anticancer treatments.

Website: www.pinotbio.com

PIPELINE INNOVATION PARTNER

Shasqi’s mission is to transform cancer treatment using click chemistry (Nobel-Prize winning technology) in humans.
Our Click Activated Protodrugs Against Cancer (CAPAC) approach separates tumor antigen binders from payloads, reuniting them at the tumor via click chemistry. This enables oncology therapies to be present only where they are needed, maximizing efficacy by minimizing efficacy-limiting toxicities.
CAPAC is clinically validated and we are advancing novel ADC & RLT therapies based on validated and new antigen targets.

Website: www.shasqi.com

Branding PARTNER

NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, have the ability to detect and treat cancer and other serious diseases.

NorthStar routinely produces copper-67 (Cu-67) and is poised to be the first commercial-scale producer of non-carrier-added (n.c.a.) actinium-225 (Ac-225).

NorthStar’s Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs.

Website: www.northstarnm.com

Branding PARTNER

Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) with more than 50 years’ experience in providing small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries.

Sterling manages the most complex API and API intermediate challenges from proof-of-concept to commercial manufacture, as well as Antibody Drug Conjugate (ADC) development and manufacturing services.

Sterling has six facilities across the UK, USA and Europe, employing 1,350+ people.

Website: www.sterlingpharmasolutions.com

View Agenda

Buy Ticket

To the top

Partners

VENUE

LOCATION

OUR CONTACT DETAILS

JOIN OUR TEAM

ABOUT US

EXPLORE OUR PRODUCTS

SEARCH